This is a repository copy of The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/167264/

Version: Published Version

Article:
von Doeveren, Thomas, Nakauma-Gonzalez, Jose A., Mason, Andrew Stephen orcid.org/0000-0002-8222-3974 et al. (14 more authors) (2020) The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder. International Journal of Cancer. pp. 1-7. ISSN 1097-0215

https://doi.org/10.1002/ijc.33327

Reuse
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:
https://creativecommons.org/licenses/

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder

Thomas van Doeveren¹ | Jose A. Nakauma-Gonzalez¹,²,³ | Andrew S. Mason⁴,⁵ | Geert J. L. H. van Leenders⁶ | Tahlita C. M. Zuiverloon¹ | Ellen C. Zwarthoff⁶ | Isabelle C. Meijsen⁶ | Angelique C. van der Made⁶ | Antoine G. van der Heijden⁷ | Kees Hendriks⁸ | Bas W. G. van Rhijn⁸,⁹ | Charlotte S. Voskuilen⁸ | Job van Riet¹,³ | Winand N. M. Dinjens⁶ | Hendrikus J. Dubbink⁶ | Harmen J. G. van de Werken¹,³ | Joost L. Boormans¹

¹Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands
²Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands
³Cancer Computational Biology Center, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands
⁴Jack Birch Unit for Molecular Carcinogenesis, Department of Biology, The University of York, York, UK
⁵York Biomedical Research Institute, The University of York, York, UK
⁶Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands
⁷Department of Urology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
⁸Department of Urology, Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
⁹Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany

Correspondence
Thomas van Doeveren, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Email: t.vandoeveren.1@erasmusmc.nl

Funding Information
Dutch Uro-Oncology Study Group (DUOS)

Abstract
The risk of developing urothelial carcinoma of the bladder (UCB) in patients treated by radical nephroureterectomy (RNU) for an upper urinary tract urothelial carcinoma (UTUC) is 22% to 47% in the 2 years after surgery. Subject of debate remains whether UTUC and the subsequent UCB are clonally related or represent separate origins. To investigate the clonal relationship between both entities, we performed targeted DNA sequencing of a panel of 41 genes on matched normal and tumor tissue of 15 primary UTUC patients treated by RNU who later developed 19 UCBs. Based on the detected tumor-specific DNA aberrations, the paired UTUC and UCB(s) of 11 patients (73.3%) showed a clonal relation, whereas in four patients the molecular results did not indicate a clear clonal relationship. Our results support the hypothesis that UCBs following a primary surgically resected UTUC are predominantly clonally derived recurrences and not separate entities.

Abbreviations: AI, allelic imbalance; Indels, insertion/deletion; LS, Lynch syndrome; NGS, next-generation sequencing; SNP, single-nucleotide polymorphism; SNV, single-nucleotide variants; TCGA, The Cancer Genome Atlas; UCB, urothelial carcinoma of the bladder; UTUC, upper urinary tract urothelial carcinoma; VAF, variant allelic frequency.

Thomas van Doeveren and Jose A. Nakauma-Gonzalez contributed equally to this study.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.
1 | INTRODUCTION

Patients undergoing radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC) have 22% to 47% risk of developing a subsequent urothelial carcinoma of the bladder (UCB) within 2 years. Two hypotheses have been proposed for this increased risk. Firstly, the entire urinary tract of patients with urothelial carcinoma undergoes a "field change," priming the tissue for independent transformations. Upper and lower tract tumors therefore develop independently from one another and are not clonally related. Secondly, by intraluminal seeding or intraepithelial spread, cancer cells from the primary UTUC implant in the bladder wall and develop into a UCB resulting in clonally related tumors. Recently, we performed a systematic review of the literature on the clonal relationship between UTUC and paired UCB and found that 94% of the cases originated from the same progenitor cell. However, the molecular techniques used differed largely over time and research groups, plus only a limited number of studies used comprehensive large-scale DNA sequencing techniques, which enables more conclusive assessment of a clonal relation between these two entities.

In our study, we used targeted DNA next-generation sequencing (NGS) to analyze the clonal relationship of primary UTUC and subsequent UCB in patients treated with an RNU based on shared genomic alterations.

2 | MATERIALS AND METHODS

2.1 | DNA extraction

Tumor hematoxylin and eosin slides were reviewed by an expert genitourinary pathologist (GvL) and regions containing ≥50% tumor cells were selected for DNA isolation (Supplementary Table 2). Tumor and corresponding normal tissue sections were manually microdissected in 5% Chelex 100 Resin (Bio-Rad, Hercules, CA) cell lysis solution (Promega, Madison, WI). DNA was extracted by proteinase K (Roche, Mannheim, Germany) digestion at 56°C. Proteinase K was inactivated for 10 minutes at 95°C after which the samples were centrifuged for 5 minutes at 14000 rpm to collect cell debris and chelexresin. Finally, DNA was collected into new tubes and the concentration was measured by using a Qubit 2.0 fluorometer (Thermo Fisher Scientific, Waltham, MA), as described by the manufacturer.

2.2 | Next-generation targeted sequencing

For targeted NGS, a custom-made cancer panel was designed using the AmpliSeq designer (Thermo Fisher Scientific, Waltham, MA). This panel comprised 330 amplicons covering 41 genes, multiple hotspot regions in various cancer-related genes and 154 single nucleotide polymorphisms in multiple tumor suppressor regions to detect copy number variations (Table 2 and Supplementary Table 3). NGS was performed with the Ion Torrent platform using supplier's materials and protocols (Thermo Fisher Scientific). Median coverage depths were 1994x for UTUC, 1712x for UCB and 1914x for the adjacent normal tissue. Libraries were made using the Ion AmpliSeq Library Kit plus-384 LV, template was prepared with the Ion 510/520/530 Chef kit and sequencing was performed on a 530-chip using the Ion S5 system. Data were analyzed using SeqPilot (JSI medical systems). To correct for potential germline mutations, NGS was also performed on DNA isolated from matched nonmalignant kidney tissue. The final tumor cell percentage was calculated based on the DNA quality and quantity and the results of the NGS.

2.3 | Genomic alterations

A visual inspection by an experienced technician (ICM) and clinical scientist (HJD) in molecular pathology making use of Torrent Variant Caller and SNPitty was carried out to identify the genomic alterations. These genomic alterations were stored in VCF format. Figure 1 summarizes all detected genomic alterations; single-nucleotide variants (SNVs), indels, allelic imbalance (AI), amplifications and homozygous deletions. For AI analysis, single nucleotide polymorphisms with a total coverage of >100 reads were included. For any informative SNP without AI, a variant allele frequency (VAF) of 0.5 was expected. With a VAF of <0.5 (relative loss of variant allele) or a VAF of >0.5 (relative loss of reference allele), AI was indicated.

What's new?

Patients treated by radical nephroureterectomy for upper urinary tract cancer have an increased risk of developing bladder carcinoma following surgery. It remains unclear, however, whether the upper urinary tract cancer and subsequent bladder carcinoma are clonally related or have separate origins. This targeted DNA sequencing study shows that almost 75% of patients have tumors that are clonally related, suggesting that seeding of tumor cells is the main mechanism of bladder carcinoma development following radical nephroureterectomy. This result underscores the need to minimize the risk of seeding during surgery and/or diagnostic ureterorenoscopy plus biopsy, and to apply peri-operative intravesical instillations with chemotherapy.

KEYWORDS

bladder carcinoma, clonality, upper urinary tract carcinoma, urothelial carcinoma
| Variable | Value |
|----------|-------|
| **Patient characteristics, n = 15** | |
| Male sex—no. (%) | 8 (53.3%) |
| Age, years, median (IQR) | 67 (12.5) |
| Smoking status | |
| Never | 3 (20.0%) |
| Former | 9 (60.0%) |
| Current | 3 (20.0%) |
| **Treatment characteristics, n = 15** | |
| Preoperative URS—no. (%) | 10 (66.7%) |
| Bladder cuff removal—no. (%) | 10 (66.7%) |
| Perioperative systemic chemotherapy—no. (%) | 0 (0.0%) |
| Perioperative intravesical instillation with chemotherapy—no. (%) | 2 (13.3%) |
| **UTUC characteristics, n = 15** | |
| Laterals—no. (%) | |
| Left | 7 (46.7%) |
| Right | 8 (53.3%) |
| Localizations—no. (%) | |
| Renal pelvis | 9 (60.0%) |
| Ureter | 6 (40.0%) |
| Pathological T-stage—no. (%) | |
| pTa | 9 (60.0%) |
| pT1 | 1 (6.7%) |
| pT2 | 3 (20.0%) |
| pT3 | 2 (13.3%) |
| Tumor grade (WHO 1973)—no. (%) | |
| Grade 1 | 1 (6.7%) |
| Grade 2 | 9 (60.0%) |
| Grade 3 | 5 (33.3%) |
| Tumor grade (WHO 2004/2016)—no. (%) | |
| Low grade | 5 (33.3%) |
| High grade | 10 (66.7%) |
| Pathological N-stage—no. (%) | |
| pNx | 14 (93.3%) |
| pN0 | 1 (6.7%) |
| **UCB characteristics, n = 19** | |
| Pathological T-stage—no. (%) | |
| pTis | 2 (10.5%) |
| pTa | 15 (79.0%) |
| pT1 | 2 (10.5%) |
| Tumor grade (WHO 1973)—no. (%) | |
| Grade 1 | 2 (10.5%) |
| Grade 2 | 10 (52.6%) |
| Grade 3 | 7 (36.8%) |
| Tumor grade (WHO 2004/2016)—no. (%) | |
| Low grade | 8 (42.1%) |
| High grade | 11 (57.9%) |

**Time to UCB (months), median (IQR)**

16.0 (11.5)

Abbreviations: IQR, interquartile range; RNU, radical nephroureterectomy; TNM stage, based on seventh TNM classification of malignant tumors; UCB, urothelial carcinoma of the bladder; URS, ureterorenoscopy; UTUC, upper urinary tract urothelial carcinoma.
2.4 Clonality assessment

A possible clonal relationship between UTUC and subsequent UCB(s) was assessed by interrogating all SNVs including synonymous mutations, amplifications, indels and supportive information on AI. To identify if a mutation that was reported in one sample but not in the paired other sample because of insufficient quality reads or absence of that mutation, the following steps were undertaken. A list of all mutations reported in

| Gene     | Exons covered | Gene or region | Numbers of SNPs included |
|----------|---------------|----------------|--------------------------|
| CDKN2A   | Chr1p         |                | 11 SNPs                  |
| PTEN     | Chr8p         |                | 9 SNPs                   |
| TP53     | Chr7          |                | 9 SNPs                   |
| AKT1     | Exon 3        | Chr19q         | 9 SNPs                   |
| ALK      | Exons 20-22-25| APC            | 9 SNPs                   |
| Amel_X   | Not applicable| ARID1A         | 8 SNPs                   |
| Amel_Y   | Not applicable| ATM            | 9 SNPs                   |
| APC      | Exon 14       | BRCA1          | 9 SNPs                   |
| ARAF     | Exon 7        | BRCA2          | 9 SNPs                   |
| BRAF     | Exons 11, 15  | CDKN2A         | 9 SNPs                   |
| CHEK2    | Exons 4, 5, 12, 13 | FHIT | 9 SNPs |
| CTNNB1   | Exons 3, 7, 8 | PTEN           | 9 SNPs                   |
| EGRF     | Exons 18-21   | RB1            | 9 SNPs                   |
| ERBB2    | Exons 19-21   | SMAD4          | 9 SNPs                   |
| EXH2     | Exon 16       | STK11          | 9 SNPs                   |
| FBXW7    | Exons 9, 10   | TP53           | 9 SNPs                   |
| FGFR1    | Exons 7, 9    | VHL            | 9 SNPs                   |
| FGFR2    | Exons 7, 9    |                |                          |
| FGFR3    | Exons 7, 9    |                |                          |
| FOXL2    | Exon 3        |                |                          |
| GNA11    | Exons 4, 5    |                |                          |
| GNAS     | Exons 8, 9    |                |                          |
| HRAS     | Exons 2-4     |                |                          |
| IDH1     | Exon 4        |                |                          |
| IDH2     | Exon 4        |                |                          |
| KIT      | Exons 8, 9, 11, 13, 14, 17 | | |
| KRAS     | Exons 2-4     |                |                          |
| MAP2K1   | Exons 2, 3    |                |                          |
| MET      | Exons 2, 14, 19|               |                          |
| MYD88    | Exon 5        |                |                          |
| NOTCH1   | Exons 26, 27  |                |                          |
| NRAS     | Exons 2-4     |                |                          |
| PDGFRa   | Exons 12, 14, 18|              |                          |
| PIK3CA   | Exons 10, 21  |                |                          |
| POLD1    | Exons 12      |                |                          |
| POLE     | Exons 9, 13   |                |                          |
| RAF1     | Exon 7        |                |                          |
| RET      | Exons 11, 16  |                |                          |
| RNF43    | Exons 3, 4, 9 |                |                          |
| SMAD4    | Exons 3, 9, 12|                |                          |
| STK11    | Exons 4, 5, 8 |                |                          |
| TERT promoter | Promoter region | | |

Note: Diagnostic V5.1 next-generation sequencing panel. Erasmus Medical Center, Rotterdam.
one patient (UTUC and UCBs) was gathered. For every specific position, reads for normal and tumor samples (Phred quality score above ≥ 15) were subtracted from the BAM files using the bam2R function from the deepSNV (v1.30.0) R package. Only sites where all samples (tumor and normal) reported a minimum total reads of 30x were included for clonality analysis. The total number of reads was the sum of reference reads plus alternative reads. The VAF from normal tissue samples (VAF\textsubscript{N}) was used as reference to determine SNVs. SNVs and indels were identified when VAF\textsubscript{N} < 0.10 and VAF\textsubscript{T} > 0.10. Three samples, the UCBs from Patients II, V and VI, showed some degree of DNA degradation, and the VAF\textsubscript{T}...
frequencies of hotspot mutations in urothelial carcinoma, the presence of a specific SNV or indel. The frequency \( f = x/n \), where \( x \) is the number of tumors with a specific SNV and \( n \) is the total number of tumors based on \( n = 411 \) bladder cancer tumors from the TCGA cohort. Note that hotspot mutations would have high frequencies and rare mutations would have very low frequencies. When mutations have not been reported in the TCGA data set (in case of indels and rare SNVs), the frequency of these mutations was estimated as \( f = m/(n + m) \), where \( m \) is the number of patients carrying that specific SNV or indel. The frequencies of hotspot mutations in TERT promoter (\( p\text{TERT} \)) have not been included in the TCGA data set. We completed the data set by adding reported frequencies of \( p\text{TERT} \) C228T (64%) and C250T (13%) mutations from a study by Allory et al. Based on the marginal frequency of all SNVs and indels, the likelihood ratio test was applied to estimate the probability of a clonal origin of the paired UTUC and UCB.11 \( P \) values were adjusted with the Benjamin and Hochberg method and adjusted \( P \) values < .05 were considered significant.

3 | RESULTS

In total, 15 patients with primary UTUC, treated by RNU, who subsequently developed 19 UCBs, treated by transurethral resection of the bladder, were included. Patient, treatment and tumor characteristics of the study population are listed in Table 1 and Supplementary Table 1. Shared genomic variants revealed that UTUC and paired UCB(s) were clonally related in 11 of 15 patients (73.3%) (Figure 1). No significance (\( P_{\text{Adj}} = .086 \)) was found for the single-shared TERT (C250T) mutation in Patient IV; however, comparable AI patterns supported clonal origin. Patient XIII, diagnosed with Lynch syndrome (LS), only shared a Fibroblast Growth Factor Receptor (FGFR)-3 mutation (p.R248C; c.742C>T) between both tumors. However, as this mutation only occurs in less than 1% of urothelial carcinoma, a clonal relationship remained statistically significant (\( P_{\text{Adj}} = .025 \)). Patients II and XV also exhibited only a single-shared mutation between both tumors, but as these alterations are common hotspot mutations in urothelial carcinoma, the presence in both entities did not unambiguously reflect a clonal relation. In Patients I and VI, we did not observe any shared somatic mutations, so could not support a clonal relationship.

4 | DISCUSSION

Studies that used large-scale sequencing techniques to assess the clonality of UTUC and paired UCB are scarce. In 2017, Du et al analyzed five patients with synchronous UTUCs (\( n = 9 \)) and UCBs (\( n = 4 \)) by whole exome sequencing.14 Tumors were clonally related in only two patients; a lower proportion than we found in the present study. Exposure to aristoclastic acid was linked to tumor development in all five patients, which possibly affected the entire urothelium leading to field cancerization. Audenet et al reported on a cohort of 29 patients with paired UTUC and UCB, and found all tumors to be clonally related, although this cohort also included patients with a history of primary UCB and some exhibited synchronous tumors.15 In the present study, we only included patients with primary UTUC and metachronous UCB(s); an approach which more accurately reflects the natural course of surgically treated UTUC patients.

The observed differences in cohort clonality may reflect patient idiosyncrasies, but also highlight remaining technical challenges. Targeted panels do not to cover all genomic aberrations, so clonality might have been underestimated in our study. Shared alterations could have been missed due to the extent of this panel, which increases the likelihood that the UCBs, which were found not to be clonally related, could have been clonally derived recurrences. Reductions in sequencing cost, and the application of whole genome or exome RNA-DNA sequencing, offer opportunities to expand the search for clonal markers. Tumor heterogeneity may be an alternative explanation for the ~25% of paired tumors we analyzed which did not appear clonally related: it cannot be unambiguously excluded that clonality was masked for these tumors. Furthermore, as a relatively rare cancer, there are limited data on UTUC-specific mutation frequencies. Pertinently, recent work proposed enrichment of the FGFR3 p.R248C amino acid substitution in LS-linked UTUC, and so it is debatable whether this shared alteration alone indicates a clonal relationship in Patient XIII. Particularly when LS patients may exhibit a higher probability of developing multiple urinary tract tumors.16 Notwithstanding these limitations, our observation that almost 75% of the paired tumors were clonally related strongly suggests that seeding of tumor cells from the upper urinary tract to the bladder represents the most important mechanism of UCB development following RNU. Importantly, three patients in our cohort developed multiple subsequent UCBs, and all tumors were clonally related to the primary UTUC, which further supports the mechanism of seeding of tumor cells.

5 | CONCLUSIONS

The results of our study underscore the rationale to (a) minimize the risk of seeding of tumor-cells during RNU; (b) carefully consider the need for diagnostic work-up by ureterorenoscopy and biopsy, which can dissociate cancer cells, and (c) apply perioperative intravesical instillations with chemotherapy to kill cancer cells floating in urine. Large-scale genomic characterization of a properly selected cohort of UTUC and paired UCB using unbiased sequencing techniques will overcome the aforementioned limitations and will further clarify clonal relationships between in-patient upper and lower tract urothelial carcinomas.
ACKNOWLEDGEMENTS
Thomas van Doeveren received additional support for the present study from the Dutch Uro-Oncology Study Group (DUOS); PhD candidate sponsored by the Dutch Cancer Society, outside the submitted work. Andrew S. Mason is a York Against Cancer 30th Anniversary Research Fellow.

CONFLICT OF INTEREST
J. L. Boormans reports on consultancy work for MSD, Janssen, Ambu, Health care and Ismar, during the conduct of the study; and received a research grant from Decipher Biosciences. All other authors report no conflict of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICS STATEMENT
No approval was required for our study.

ORCID
Thomas van Doeveren https://orcid.org/0000-0002-9697-4293
Jose A. Nakauma-Gonzalez https://orcid.org/0000-0002-7580-106X
Andrew S. Mason https://orcid.org/0000-0002-8222-3974
Geert J. L. van Leenders https://orcid.org/0000-0003-2176-9102
Tahlita C. M. Zuiverloon https://orcid.org/0000-0003-0991-0812
Ellen C. Zwarthoff https://orcid.org/0000-0002-9853-4953
Antoine G. van der Heijden https://orcid.org/0000-0002-8839-8601
Charlotte S. Voskuilen https://orcid.org/0000-0002-6507-118X
Job van Riet https://orcid.org/0000-0001-7767-7923
Winand N. M. Dinjens https://orcid.org/0000-0002-9298-8380
Hendrikus J. Dubbink https://orcid.org/0000-0002-2160-5207
Harmen J. G. van de Werken https://orcid.org/0000-0002-9794-1477
Joost L. Boormans https://orcid.org/0000-0002-5127-0436

REFERENCES
1. Roupret M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol 2020.
2. Harris AL, Neal DE. Bladder cancer—field versus clonal origin. N Engl J Med. 1992;326:759-761.
3. Habuchi T. Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications. Int J Urol. 2005;12:709-716.
4. van Doeveren T, van de Werken HJG, van Riet J, et al. Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: are they clonally related? A systematic review. Urol Oncol. 2020;38(6):590-598.
5. Puis MA, Geurts-Giele WR, von der TJH, et al. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer. Lung Cancer. 2020;140:46-54.
6. Dubbink HJ, Atmodimedjo PN, van Marion R, et al. Diagnostic detection of allelic losses and imbalances by next-generation sequencing: 1p/19q co-deletion analysis of gliomas. J Mol Diagn. 2016;18:775-786.
7. Van Bockstal MR, Aghafozo MC, van Marion R, et al. Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification. Mol Oncol. 2020;14:671-685.
8. van Riet J, Krol NMG, Atmodimedjo PN, et al. SNPitty: an intuitive web application for interactive B-allele frequency and copy number visualization of next-generation sequencing data. J Mol Diagn. 2018;20:166-176.
9. Geurts-Giele WR, van Verschuer VM, van Deurzen CH, et al. Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant. Mod Pathol. 2017;30:15-25.
10. Gerstung M, Beisel C, Rechsteiner M, et al. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun. 2012;3:811.
11. Ostrovnaya I, Seshan VE, Begg CB. Using somatic mutation data to test tumors for clonal relatedness. Ann Appl Stat. 2015;9:1533-1548.
12. Mauguen A, Seshan VE, Begg CB, Ostrovnaya I. Testing clonal relatedness of two tumors from the same patient based on their mutational profiles: update of the clonality R package. Bioinformatics. 2019;35:4776-4778.
13. Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014;65:360-366.
14. Du Y, Li R, Chen Z, Wang X, Xu T, Bai F. Mutagenic factors and complex clonal relationship of multifocal urothelial cell carcinoma. Eur Urol. 2017;71:841-843.
15. Audenet F, Isharov S, Cha EK, et al. Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma. Clin Cancer Res. 2018;24(3):967-976.
16. Donahue TF, Bagrodia A, Audenet F, et al. Genomic characterization of upper-tract urothelial carcinoma in patients with lynch syndrome. JCO Precis Oncol. 2018;2:1-13.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: van Doeveren T, Nakauma-Gonzalez JA, Mason AS, et al. The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder. Int. J. Cancer. 2020;1–7. https://doi.org/10.1002/ijc.33327